Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
Search results for: lungs
What Our Colleagues Should Know: Integrated Care for the Lungs
Multi-system diseases have unique challenges. And Dr. Aryeh Fischer says that when treating patients with interstitial lung disease, pulmonologists and rheumatologists must better understand “how we [both] approach our shared diseases.”
What Listening to Lungs Might Teach About Rheumatic Disease
One of your first clinical assignments as a medical student was likely to have been the lung exam. Its key descriptors may still resonate in your mind: inspection, palpation, percussion and auscultation. Proudly parading down the hospital corridors, your newly purchased stethoscope snugly tucked inside your lab coat pocket, you carefully place its cold metal…
Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD
In a recent interview, Aryeh Fischer, MD, addresses the importance of checking patients with autoimmune diseases for interstitial lung disease, noting that advances in technology and awareness can lead to early detection and affect patient outcomes…
ACPA-Positive & ACPA-Negative Patients with RA: The Difference Begins in the Lungs
A new study from Stockholm, Sweden, strengthens the link between the lungs and anti-citrullinated protein antibody (ACPA)–positive RA. After analyzing the bronchial tissue of untreated patients with early RA, researchers found the patients’ lungs had signs of immune cell accumulation and activation…
Lungs Are Particularly Vulnerable in Patients with Systemic Rheumatic Disease
In an observational study, physicians found that systemic rheumatic disease exacerbation and treatment-related infections were often related to the lungs…
Potential Biologic Drug Treatment for IgG4-RD Identified
Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…
Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
A&R Editor-in-Chief Daniel H. Solomon, MD, MPH, Reflects on the Journal, His Role & Its Future
New clinical features, opinion pieces and much more—outgoing Arthritis & Rheumatology Editor-in-Chief Daniel H. Solomon, MD, MPH, discusses how the journal has evolved and where it’s going.
mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis
FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
- 1
- 2
- 3
- …
- 26
- Next Page »